1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the first-line treatment of chronic lymphocytic leukaemia

Technology appraisal guidance [TA174] Published date: 22 July 2009

  • Guidance
  • Tools and resources
  • Information for the public
  • History

Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix B proposal paper presented to the Institute's Guidance Executive

Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix B proposal paper presented to the Institute's Guidance Executive Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix B proposal paper presented to the Institute's Guidance Executive
20 January 2014
(446.11 Kb 9 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 14 January 2014